{"filings":[{"id":95834,"accession_number":"0001628280-26-031669","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Foghorn Q1 net loss $19.9M, cash $183.6M; FHD-909 Phase 1 on track; IND for two degraders expected 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 net loss $19.9M (vs $18.8M loss Q1 2025); collaboration revenue $3.3M (down from $6.0M).","Cash, equivalents & marketable securities $183.6M as of Mar 31, 2026; cash runway into H1 2028.","Lead program FHD-909 Phase 1 dose-escalation on track; preclinical combo with anti-PD-1 showed complete tumor regression and immune memory.","IND expected 2027 for Selective CBP degrader FHT-171 and Selective EP300 degrader; ARID1B degrader advancing to in vivo proof-of-concept in 2026.","R&D expenses declined to $18.3M (from $21.6M) driven by lower Lilly-partnered program costs and facilities expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":3267000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95833,"accession_number":"0001628280-26-026259","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Foghorn presents preclinical data at AACR: FHD-909 combo shows complete regression and immune memory","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FHD-909 (SMARCA2 inhibitor) plus anti-PD-1 achieved complete tumor regression and immune memory in preclinical SMARCA4-mutant models.","Selective CBP degrader FHT-171 showed strong anti-tumor activity and favorable tolerability in heavily pretreated ER+ breast cancer PDX models.","Selective EP300 degrader outperformed clinical benchmark inobrodib in multiple myeloma models, including pomalidomide-resistant xenografts.","Cereblon-based selective ARID1B degraders achieved robust degradation with potential for oral bioavailability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109165,"accession_number":"0001628280-26-016805","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Foghorn Therapeutics reports 2025 net loss $74.3M, cash runway into H1 2028; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss improved to $74.3M in 2025 from $86.6M in 2024; collaboration revenue rose to $30.9M.","Cash, equivalents, and marketable securities $158.9M at Dec 31, 2025; extended runway into H1 2028 after $50M Jan 2026 financing.","Ryan Maynard appointed CFO in Feb 2026, bringing over 25 years of biopharma finance experience.","Lead candidate FHD-909 Phase 1 dose-escalation on track; collaboration with Lilly advancing.","Selective CBP and EP300 degrader programs on track for IND-enabling studies in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109164,"accession_number":"0001628280-26-010377","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Foghorn Therapeutics appoints Ryan Maynard as CFO, replacing interim CFO Jeff Sacher","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ryan Maynard appointed CFO effective February 23, 2026; succeeds Jeff Sacher (interim CFO).","Compensation: $510k base salary, 40% bonus target, $90k signing bonus, 400k share option grant.","Maynard brings 25+ years experience; most recently CFO of Cara Therapeutics (2022-2025).","Previously CFO at Rigel Pharmaceuticals, LetsGetChecked, and Blade Therapeutics; started career at Ernst & Young.","Maynard raised over $1B in financings and executed reverse merger for Cara with Tvardi Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109163,"accession_number":"0001193125-26-009885","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Foghorn Therapeutics raises $50M in equity financing at 30% premium; extends cash into H1 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$50M from sale of 2M shares ($6.71) and pre-funded warrants; includes Series 1 warrants ($13.42) and Series 2 warrants ($20.13).","Offering priced at 30% premium to Jan 9, 2026 closing; investors include BVF Partners, Deerfield Management, Flagship Pioneering, and a biotech mutual fund.","Pro forma cash, cash equivalents and marketable securities of $208.9M (unaudited) as of Jan 13, 2026; cash runway extended into first half of 2028.","FHD-909 (SMARCA2 inhibitor) Phase 1 dose-escalation trial on track; enrollment in NSCLC patients progressing as planned.","Selective CBP degrader on track to be IND-ready in 2026; selective EP300 degrader expected to enter IND-enabling studies in 2026; ARID1B degrader advancing to in vivo PoC in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125665,"accession_number":"0001628280-25-055215","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Foghorn Therapeutics appoints Jeff Sacher as interim CFO effective Dec 3, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeff Sacher appointed as Treasurer and interim CFO, effective immediately; company continues search for permanent CFO.","Sacher is a CFO at Danforth Advisors, which will be paid an hourly rate for interim CFO services plus expenses.","Sacher has 35 years in biotech and investment banking, with an MBA from Kellogg and a BA from Cornell.","No family relationships with any executive officers or directors; no other arrangements for his appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125664,"accession_number":"0001628280-25-050683","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Foghorn Therapeutics releases November 2025 investor presentation highlighting precision therapeutics","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation dated November 2025 focuses on the company's unique biology and precision therapeutics platform.","No specific financial results or operational updates disclosed in the filing.","The presentation is intended for use in meetings with investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125663,"accession_number":"0001628280-25-049236","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Foghorn Q3 net loss narrows to $15.8M; CFO Humer resigns; cash runway into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["CFO Kristian Humer resigns effective Nov 14, 2025 to pursue other opportunity; no disagreement with company.","Q3 2025 net loss $15.8M vs $19.1M YoY; collaboration revenue $8.2M (vs $7.8M); R&D expenses $20.0M.","Cash, equivalents, and marketable securities $180.3M as of Sept 30, 2025; provides cash runway into 2028.","FHD-909 (SMARCA2 inhibitor) Phase 1 trial in SMARCA4-mutated NSCLC enrolling well; combination data with pembrolizumab and KRAS inhibitors.","Selective CBP degrader IND-ready in 2026; EP300 degrader IND-enabling studies in 2026; ARID1B degrader advancing to in vivo POC in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":21662000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125662,"accession_number":"0001628280-25-047322","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Foghorn Therapeutics advances three degrader programs; ARID1B degrader selectively degrades ARID1B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Selective ARID1B degrader shows selective binding and degradation, potentially relevant in up to 5% of solid tumors (endometrial, gastric, bladder, NSCLC).","Selective CBP degrader CBPd-171 advancing to non-GLP toxicology studies in Q4 2025; IND-ready in 2026 for EP300-mutant cancers and ER+ breast cancer.","Selective EP300 degrader demonstrates efficacy in >70% of hematological malignancies and IMiD-resistant multiple myeloma without thrombocytopenia.","All three programs leverage novel degrader technology to overcome historical challenges of high homology with ARID1A, CBP/EP300.","Company hosting virtual investor event on October 30, 2025 at 12 p.m. ET to present data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142390,"accession_number":"0001822462-25-000007","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Foghorn Therapeutics releases September 2025 investor presentation without new material disclosures","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation reiterates company focus on unique biology, precision therapeutics, and broad impact.","No new financial, clinical, or strategic data provided in the filing excerpt.","Intended for use in investor meetings; no guidance or material events announced.","Stock ticker FHTX listed on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142389,"accession_number":"0001628280-25-037603","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Foghorn Therapeutics Q2 2025 net loss narrows to $17.9M; cash runway into 2028; pipeline on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.9M in Q2 2025, improved from $23.0M in Q2 2024; collaboration revenue $7.6M.","Cash, equivalents and marketable securities $198.7M as of June 30, 2025; cash runway into 2028.","FHD-909 Phase 1 trial in SMARCA4-mutated NSCLC enrolling well; preclinical combo data with pembrolizumab and KRAS inhibitors.","Selective CBP degrader targeting IND in 2026; selective EP300 and ARID1B degrader updates expected Q4 2025.","R&D expenses decreased to $21.8M from $23.8M; G&A expenses decreased to $6.9M from $7.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":13509000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142388,"accession_number":"0001628280-25-033784","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Foghorn Therapeutics signs new 9-year lease for 72,846 sq ft HQ in Watertown, MA, terminates Cambridge lease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New lease at 99 Coolidge Avenue, Watertown for 72,846 sq ft; annual base rent starts at $87/sq ft with partial abatement in years 1-2.","Rent commencement expected October 1, 2026, followed by 3% annual escalations starting October 1, 2027.","Terminates 81,441 sq ft lease at 500 Technology Square, Cambridge (originally through Sept 2028) via Lease Termination Agreement.","Security deposit of $2 million; two 5-year renewal options; space for HQ and R&D operations.","Early occupancy of office portion targeted for December 15, 2025, with full delivery of build-out by December 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160425,"accession_number":"0001628280-25-031819","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Foghorn Therapeutics stockholders elect four Class II directors, ratify Deloitte as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Stuart Duty, Neil J. Gallagher, Adrian Gottschalk, and Ian F. Smith as Class II directors for three-year terms.","Votes for nominees ranged from 30.9M (Ian F. Smith) to 34.6M (Neil J. Gallagher); 8.68M broker non-votes.","Ratified Deloitte & Touche LLP as independent auditor for FY2025 with 43.34M votes for, 16,978 against.","Total shares present at meeting: 43,369,822 out of 55,721,340 outstanding; all proposals approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160424,"accession_number":"0001628280-25-025302","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Foghorn Therapeutics Q1 net loss narrows to $18.8M; pipeline advances with FHD-909 Phase 1 and degrader programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 net loss $18.8M vs $25.0M in Q1 2024; collaboration revenue $6.0M (up from $5.1M).","Cash, equivalents, and marketable securities $220.6M; cash runway into 2027.","FHD-909 (SMARCA2 inhibitor) Phase 1 dose escalation in SMARCA4-mutated cancers ongoing, NSCLC primary target.","Selective CBP degrader targeting IND in 2026; ARID1B and EP300 degrader program updates expected H2 2025.","Board appointments: Neil Gallagher (Syndax President) and Stuart Duty (former Guggenheim Senior MD) in May 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":5952000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160423,"accession_number":"0001628280-25-021506","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Foghorn Therapeutics appoints Neil Gallagher and Stuart Duty to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stuart Duty and Neil Gallagher appointed effective May 1, 2025 as Class II directors.","Each granted initial option to purchase 50,000 shares vesting over three years.","Duty to serve on Audit Committee; Gallagher on Science Committee.","Duty receives annual cash retainers $40,000 board + $7,500 audit; Gallagher $40,000 + $5,000 science.","Audit Committee now has three independent members, regaining Nasdaq compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160422,"accession_number":"0001628280-25-020257","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Foghorn presents AACR preclinical data for FHD-909 and CBP/EP300 degraders; Phase 1 ongoing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FHD-909 (SMARCA2 inhibitor) Phase 1 trial ongoing in SMARCA4-mutated solid tumors; NSCLC primary target.","Preclinical combo data: FHD-909 synergistic with pembrolizumab and KRAS inhibitors, supporting clinical exploration.","Selective CBP degrader synergistic with paclitaxel and abemaciclib in ER+ breast cancer models.","Selective EP300 degrader shows preclinical activity in DLBCL and multiple myeloma; no thrombocytopenia.","ARID1B degrader program update expected in 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178687,"accession_number":"0001628280-25-014475","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Foghorn Therapeutics furnishes investor presentation; no material new information","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company filed an investor presentation dated March 2025 under Regulation FD.","Presentation intended for use in meetings with investors; no financial results disclosed.","No specific numbers, deals, or guidance changes included in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178686,"accession_number":"0001628280-25-014136","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Foghorn Therapeutics reduces ATM program capacity from $200M to $100M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 1 to Sales Agreement with TD Cowen lowers maximum shares to be sold from $200M to $100M.","Other terms of the at-the-market offering program remain unchanged; no new public offering announced.","Amendment effective March 20, 2025; shares sold pursuant to previously effective shelf registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178685,"accession_number":"0001628280-25-010916","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Foghorn Therapeutics reports 2024 net loss $86.6M; cash runway into 2027; key pipeline milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $86.6M for FY2024 vs $98.4M in 2023; collaboration revenue $22.6M (down from $34.2M).","Cash, equivalents and marketable securities $243.7M as of Dec 31, 2024, providing cash runway into 2027.","FHD-909 Phase 1 trial enrolling for SMARCA4-mutated cancers (NSCLC primary); preclinical combo data at AACR 2025.","Selective degradation of ARID1B achieved; program update expected in 2025. CBP and EP300 degraders progressing towards IND.","Research and development expenses $94.5M (down from $109.7M); G&A $28.4M (down from $32.4M)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178684,"accession_number":"0001628280-25-003385","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Foghorn Therapeutics furnishes February 2025 investor presentation; no specific financial updates in filing excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation furnished as Exhibit 99.1 for use in investor meetings.","No key metrics, guidance, or material corporate events disclosed in available content.","Ticker symbol FHTX on Nasdaq Global Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178683,"accession_number":"0001628280-25-002466","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Foghorn Therapeutics receives Nasdaq non-compliance notice over audit committee composition","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Foghorn on Jan 23, 2025 that its audit committee has only two members, violating Listing Rule 5605.","Vacancy follows resignation of director Adam M. Koppel from board and audit committee effective Dec 29, 2024.","Cure period runs until earlier of next annual meeting or Dec 29, 2025; if meeting before June 27, 2025, then by June 27, 2025.","Board intends to appoint a new independent director to fill the audit committee vacancy within the cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178682,"accession_number":"0001628280-25-001226","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Foghorn reports $243.8M cash runway into 2027; pipeline milestones for FHD-909, CBP/EP300 degraders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents and marketable securities of $243.8M as of Dec 31, 2024; runway into 2027.","Phase 1 trial of oral SMARCA2 inhibitor FHD-909 for SMARCA4-mutated cancers advancing; NSCLC primary target.","Preclinical combination data for FHD-909 with pembrolizumab and KRAS inhibitors to be presented at AACR April 2025.","Selective ARID1B degradation achieved; program update expected in 2025. ARID1B implicated in up to 5% of solid tumors.","Selective CBP and EP300 degrader programs advancing with preclinical data showing anti-tumor activity and tolerability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195346,"accession_number":"0001628280-24-052539","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Adam M. Koppel resigns from Foghorn Therapeutics board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Adam M. Koppel, M.D., Ph.D., resigned from the Board effective December 29, 2024.","Resignation not due to any disagreement with the Company or Board.","Koppel served on the Audit Committee and Nominating and Corporate Governance Committee.","He was a Class II director with a term expiring at the 2025 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195345,"accession_number":"0001628280-24-051280","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Foghorn discontinues FHD-286 in AML; prioritizes pipeline and Lilly collaboration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FHD-286 + decitabine showed objective responses in Phase 1 but efficacy threshold not met for continued standalone development.","Company evaluating partnerships/ISTs for FHD-286; independent development halted.","Priorities: proprietary CBP, EP300, ARID1B programs and Lilly collaboration including SMARCA2 inhibitor FHD-909.","Cash of $267.4M as of Sept 30, 2024; runway into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195344,"accession_number":"0001628280-24-045000","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Foghorn posts Q3 net loss of $19.1M; first patient dosed in Phase 1 for FHD-909","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.8M vs $17.5M year ago; net loss $19.1M vs $14.3M year ago.","Cash $267.4M as of Sept 30, 2024; expects cash runway into 2027.","First patient dosed with FHD-909 (SMARCA2 inhibitor) in Phase 1 for SMARCA4 mutant NSCLC.","Topline Phase 1 data for FHD-286 + decitabine in AML expected by year-end 2024.","Appointed Anna Rivkin as Chief Business Officer in September 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":19746000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195343,"accession_number":"0001628280-24-042630","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Foghorn Therapeutics announces first patient dosed with FHD-909 in Phase 1 trial for SMARCA4 mutated cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed with FHD-909 (LY4050784), a first-in-class oral SMARCA2 selective inhibitor, in Phase 1 trial for SMARCA4 mutated solid tumors.","Primary target patient population is non-small cell lung cancer (NSCLC).","Lilly leads clinical development under a U.S. 50/50 co-development and co-commercialization collaboration with Foghorn.","Preclinical studies showed robust anti-tumor monotherapy activity and favorable tolerability in SMARCA2 mutant xenograft models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211605,"accession_number":"0001628280-24-035864","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Foghorn reports Q2 net loss $23M; cash $285M into 2027; FHD-286 AML data Q4; FHD-909 first patient H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.0M for Q2 2024 vs $29.5M in Q2 2023; collaboration revenue $6.9M.","Cash, equivalents & marketable securities $285.2M as of June 30, 2024; expected cash runway into 2027.","Topline Phase 1 data for FHD-286 + decitabine in r/r AML anticipated Q4 2024; includes safety, efficacy, PK/PD.","FHD-909 (SMARCA2 selective inhibitor) IND cleared May 2024; first patient dosing H2 2024 in SMARCA4 mutated NSCLC.","Selective CBP degrader IND-enabling studies on track to start Q4 2024; $110M financing closed May 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":11938000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230318,"accession_number":"0001628280-24-030137","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Foghorn Therapeutics stockholders re-elect three Class I directors, ratify Deloitte as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Scott Biller elected with 20,425,665 votes for, 4,930,514 against; 5,014,629 broker non-votes.","Thomas J. Lynch elected with 24,052,377 votes for, 1,293,218 against.","Michael Mendelsohn elected with 22,357,558 votes for, 2,988,038 against.","Ratification of Deloitte & Touche as auditor approved: 30,355,319 for, 10,376 against, 15,450 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230317,"accession_number":"0001628280-24-026294","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Foghorn Therapeutics furnishes June 2024 investor presentation; no specific financial data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation dated June 2024 was made available under Regulation FD.","No new financial or operational metrics were included in the filing.","The presentation is intended for use in investor meetings.","Company ticker FHTX; traded on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230316,"accession_number":"0001628280-24-024811","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Foghorn Therapeutics furnishes investor presentation; no specific material updates disclosed in exhibit","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation title: 'Unique biology, Precision therapeutics, Broad impact' — no additional content provided.","No financial results, pipeline updates, or guidance changes are included in this filing.","The filing does not contain any material new information beyond the existence of the presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230315,"accession_number":"0001193125-24-144934","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Foghorn Therapeutics raises ~$110M via public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 12,743,039 shares of common stock at $5.51/share and pre-funded warrants for 7,220,794 shares at $5.5099 each.","Gross proceeds estimated at ~$110M; pre-funded warrants are immediately exercisable with no expiration.","Offering closed on May 22, 2024; underwriters include Jefferies, TD Securities, and Evercore Group.","Pre-funded warrants include a 9.99% beneficial ownership cap, adjustable to up to 19.99% with 61 days' notice.","Filing made under effective shelf registration statement (Form S-3, File No. 333-262711)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230314,"accession_number":"0001628280-24-024217","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Foghorn Therapeutics files investor presentation; no specific facts available in filing text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Form 8-K furnished under Item 7.01; presentation dated May 20, 2024.","Presentation tagged 'Unique biology, Precision therapeutics, Broad impact'.","No quantitative data, pipeline updates, or financial guidance provided in the filing.","Presentation available as Exhibit 99.1 but its content is not extracted in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230313,"accession_number":"0001628280-24-020698","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Foghorn posts investor presentation; no material financial or pipeline updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted a corporate presentation to its website on May 6, 2024, for use in investor meetings.","Presentation attached as Exhibit 99.1 contains cover slide only; no specific financial data, clinical milestones, or guidance provided.","No changes to previously disclosed business strategy or pipeline status were announced.","Filing contains no earnings results, regulatory actions, or material contracts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230312,"accession_number":"0001628280-24-020454","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Foghorn Therapeutics reports Q1 2024 net loss $25.0M; cash $206.7M, runway into H1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.0M vs $30.5M YoY; collaboration revenue $5.1M, flat vs prior year.","Cash $206.7M as of Mar 31, 2024; expected cash runway into first half of 2026.","FHD-286 combo in AML dose escalation ongoing; initial clinical data expected H2 2024.","IND submitted for FHD-909 (first-in-class oral BRM selective inhibitor); Phase 1 in BRG1-mutated NSCLC expected H2 2024.","Appointed Kristian Humer as CFO in April 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":5050000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230311,"accession_number":"0001628280-24-016281","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Foghorn appoints Kristian Humer as CFO; notes upcoming pipeline milestones for 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kristian Humer appointed CFO effective April 16, replacing interim CFO Stephen DiPalma.","Compensation: $475k base salary, 40% target bonus, $87k signing bonus, 275k-share option award.","Humer brings 14+ years life science financial strategy; previously CFO/CBO at Viridian Therapeutics.","Lead program FHD-286 AML data expected H2 2024; FHD-909 (with Lilly) IND filing on track Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230310,"accession_number":"0001628280-24-015470","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Foghorn reports preclinical AACR data for FHD-909, CBP/EP300 degraders; IND on track Q2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FHD-909, a first-in-class BRM selective inhibitor, shows ~30-fold selectivity over BRG1 and dose-dependent tumor growth inhibition in BRG1 mutant xenografts.","IND filing for FHD-909 in BRG1-mutant NSCLC on track for Q2 2024; developed with Lilly.","Selective CBP degrader demonstrates tumor growth inhibition in solid tumors without thrombocytopenia or anemia.","Selective EP300 degrader shows efficacy in prostate cancer and DLBCL models with no platelet effects.","Conference call today at 5 pm ET to review pipeline updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248732,"accession_number":"0001628280-24-009540","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Foghorn Therapeutics 2023 net loss $98.4M, cash $234.1M; FHD-909 IND planned Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $98.4M in 2023 vs $108.9M in 2022; collaboration revenue $34.2M, up from $19.2M.","Cash $234.1M at Dec 31, 2023; runway into H1 2026.","FHD-286 AML combo study dose escalation ongoing; first clinical data expected H2 2024.","Lilly selects FHD-909 (BRM inhibitor) for clinical dev; IND filing Q2 2024 for BRG1-mutated NSCLC.","Preclinical data for CBP/EP300 degraders at AACR; IND-enabling studies for CBP degrader by end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248731,"accession_number":"0001628280-24-003781","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Foghorn announces Lilly selects FHD-909 for clinical development; IND planned for Q2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lilly selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development.","Lilly plans to file an IND for FHD-909 in Q2 2024 for BRG1 mutated NSCLC.","FHD-909 targets BRG1 mutant non-small cell lung cancer, exploiting BRM dependency.","Collaboration with Lilly announced Dec 2021 includes US 50/50 co-development and co-commercialization.","Foghorn and Lilly plan to present preclinical data at upcoming scientific conferences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248730,"accession_number":"0001628280-24-001504","cik":1822462,"company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Foghorn Therapeutics appoints Stephen J. DiPalma as interim CFO and Treasurer, effective Jan 16, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen J. DiPalma appointed as Treasurer and interim CFO, effective immediately.","Company continues search for a permanent CFO; DiPalma is a managing director at Danforth Advisors.","Foghorn will pay Danforth an agreed hourly rate plus expenses for DiPalma's interim CFO services.","DiPalma has served as CFO to multiple public and private life sciences companies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":247772743.98126465,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}